Figure 1.

Progression‐free survival and response to ixazomib plus fulvestrant. (A): Distribution of PFS for patients treated with fulvestrant plus ixazomib. (B): The addition of ixazomib induced a partial tumor response in a subject with fulvestrant‐resistant breast cancer. Positron emission tomography imaging results are shown from baseline and after 3 cycles of ixazomib (4 mg) plus fulvestrant. Arrows indicate corresponding tumor locations. (C): Comparison of PFS on prior fulvestrant regimen to fulvestrant/ixazomib regimen. Abbreviations: Fulv, fulvestrant; PFS, progression‐free survival.